The in vitro toxicity market has boomed owing to testing of harmful toxic compounds present in the products, such as drugs, cosmetics, and food additives. The onset of such industries has made it essential to ensure that products delivered to the end-users are safe. Therefore, recently various studies have been conducted in this direction.
- Advertising -
One of the research conducted to narrow the gap prevailing in the in vitro and in vivo drug test is by Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology at Massachusetts Institute of Technology (MIT). It is a significant study as it shows other researchers how to conduct safe study.
Moreover, it highlights some of the key findings, such as creation of advanced in vitro platforms enables replication of biological and environmental functions. This assists in prediction of drugs toxicity mechanism at a microcirculatory level.
- Advertising -
In the abovementioned study, researchers made a 3D tissue model from living human cells. They chose to make this owing to the fact that it was observed that single petri dish samples of animals are used to reach the clinical stage of humans.
This traditional method often fails to truly represent numerous cells present within the body. The researchers now combine human liver cells with gel in such a way that they perfectly make a structurally supportive model.
With the help of syringe, they pump in umbilical vein endothelial cells into hollow channels. This forms a shape of vessel and when blood flows in to this vessel to become a fully vascularized micro fluid chip.
The abovementioned chip is then kept inside a bioreactor and maintains a constant condition for proliferation and cell growth. Through this research, the students concluded that with the help of integrated bio-print vascularized construct they were able to make a more realistic liver-on-a-chip platform.
This also enabled them to promote the notion that through development of such platforms, one would be able to narrow down the gap between the in vitro and in vivo drug testing model. The call to stop animal use to test drugs has fuel up so much so that several professional have joined the “21st Century Toxicology”.
It was observed by numerous experts of the scientific world that there has been increased use of animals to assess the toxicity of drugs, chemicals, and other consumer products. As a result of which, they have decided to use data through in vitro based technologies.
Thus, they have set out 3Rs, viz., replace, refine, and reduce. It has been reported that this could be achieved by substitution of in vivo technology with that of in vitro technology.
The Food and Drug Administration (FDA) has also identified modernization of toxicology as one its priority. Furthermore, it has shown explicit interest to learn more about new methods which would assist them to achieve the desired goal.
Thus, it would be correct to draw conclusion from the abovementioned instances, the future of the in vitro toxicity testing market would be bright. It would flourish in the upcoming decades.
The similar trends are outlined in a report added by Big Market Research, titled, “In Vitro Toxicity Testing Market- Global Opportunity Analysis and Industry Forecast, 2014–2022”.
Category: Market Research Publishers and RetailersCompany profile: With the arsenal of different search reports, we help you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency. With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market ...
For more information: